• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半乳糖胺修饰的 CaCO3 纳米免疫调节剂用于针对原位肝癌的靶向和响应性免疫治疗。

A GalNAc-modified CaCO nano-immunomodulator for targeted and responsive immunotherapy against orthotopic liver cancer.

机构信息

College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Institute of Molecular and Nano Science, Shandong Normal University, Jinan, 250014, P. R. China.

Laoshan Laboratory, Qingdao, 266237, P. R. China.

出版信息

Chem Commun (Camb). 2024 Jul 30;60(62):8103-8106. doi: 10.1039/d4cc01207k.

DOI:10.1039/d4cc01207k
PMID:38993155
Abstract

A nano-immunomodulator modified with -acetylgalactosamine (GalNAc) on calcium carbonate (CaCO) was prepared for targeted and responsive immunotherapy. And the immunologic adjuvant (CpG ODNs) and doxorubicin (DOX) were released to synergistically improve immune response for treating orthotopic liver cancer.

摘要

一种经半乳糖胺(GalNAc)修饰的碳酸钙(CaCO)纳米免疫调节剂被制备用于靶向和响应性免疫治疗。同时,免疫佐剂(CpG ODNs)和阿霉素(DOX)被释放以协同提高免疫反应,用于治疗原位肝癌。

相似文献

1
A GalNAc-modified CaCO nano-immunomodulator for targeted and responsive immunotherapy against orthotopic liver cancer.半乳糖胺修饰的 CaCO3 纳米免疫调节剂用于针对原位肝癌的靶向和响应性免疫治疗。
Chem Commun (Camb). 2024 Jul 30;60(62):8103-8106. doi: 10.1039/d4cc01207k.
2
Potentiated Calcium Carbonate with Enhanced Calcium Overload Induction and Acid Neutralization Capabilities to Boost Chemoimmunotherapy against Liver Cancer.增效碳酸钙具有增强的钙超载诱导和酸中和能力,可增强肝癌的化免疫治疗。
ACS Nano. 2024 Oct 8;18(40):27597-27616. doi: 10.1021/acsnano.4c08690. Epub 2024 Sep 29.
3
A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy.自然杀伤 T 细胞纳米激动剂引发的免疫级联反应用于肝细胞癌协同免疫治疗。
Nanoscale. 2024 Jun 13;16(23):11126-11137. doi: 10.1039/d4nr00847b.
4
Smart responsive-calcium carbonate nanoparticles for dual-model cancer imaging and treatment.智能响应型碳酸钙纳米颗粒用于双模癌症成像与治疗。
Ultrasonics. 2020 Dec;108:106198. doi: 10.1016/j.ultras.2020.106198. Epub 2020 May 30.
5
MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.脂质包覆的阿霉素-碳酸钙纳米粒递送的 miR-375 克服了肝癌的化疗耐药性。
Nanomedicine. 2017 Nov;13(8):2507-2516. doi: 10.1016/j.nano.2017.05.010. Epub 2017 Jun 1.
6
CaCO nanoparticles pH-sensitively induce blood coagulation as a potential strategy for starving tumor therapy.碳酸钙纳米颗粒能够 pH 敏感地诱导血液凝固,有望成为一种饥饿肿瘤治疗的新策略。
J Mater Chem B. 2020 Feb 14;8(6):1223-1234. doi: 10.1039/c9tb02684c. Epub 2020 Jan 17.
7
Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.肝细胞癌的靶向协同治疗:用于阿霉素和索拉非尼共递送的单糖修饰脂质纳米粒
Drug Des Devel Ther. 2018 Jul 11;12:2149-2161. doi: 10.2147/DDDT.S166402. eCollection 2018.
8
pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers.pH值控制的产气矿化纳米颗粒:一种用于癌症超声成像和治疗的诊疗试剂。
ACS Nano. 2015 Jan 27;9(1):134-45. doi: 10.1021/nn506210a. Epub 2015 Jan 8.
9
Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.用聚合物胶束选择性地靶向肿瘤相关巨噬细胞和肿瘤细胞,以增强癌症的化疗-免疫治疗。
J Control Release. 2019 Nov 10;313:42-53. doi: 10.1016/j.jconrel.2019.09.021. Epub 2019 Oct 16.
10
EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.表皮生长因子受体靶向多功能聚合物囊泡阿霉素在体内诱导对原位人类肝癌的选择性和强效抑制。
Acta Biomater. 2017 Dec;64:323-333. doi: 10.1016/j.actbio.2017.10.013. Epub 2017 Oct 10.